New Lattice CrossLink-NX FPGAs Bring Power and Performance Leadership to Embedded Vision and Edge AI Applications
11.12.2019 00:00:00 EET | Business Wire | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today announced the first FPGA developed on its new Lattice Nexus™ FPGA platform, CrossLink-NX™. This new FPGA provides the low power, small form factor, reliability, and performance that developers need to create innovative embedded vision and AI solutions for communications, compute, industrial, automotive, and consumer systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005349/en/
The new CrossLink-NX FPGA from Lattice Semiconductor (Graphic: Business Wire)
According to Patrick Moorhead, President and Founder of Moor Insights & Strategy, “Technology trends like 5G connectivity, cloud-based analytics, factory automation and the smart home are driving demand for embedded vision solutions that support machine learning. However, the data latency, cost and privacy issues associated with cloud-based ML analytics have sparked interest among developers in moving more data processing from the cloud to the Edge. But doing so requires OEMs have access to Edge AI/ML inferencing solutions that offer high performance data processing, low power operation, and a small form factor.”
FPGAs are a compelling hardware platform for embedded vision and AI applications, as they perform functions in parallel. This parallel architecture significantly accelerates certain processing workloads, including data inferencing.
“Embedded vision systems are growing in complexity; many systems today use multiple image sensors, displays and cameras. Implementing such systems at the Edge, where device size and power consumption are critical, adds even more design complexity,” said Bill Pu, Co-Founder and President, Leopard Imaging. “With their very low power consumption, small size, high-performance interfaces, and robust software and IP library, Lattice CrossLink-NX FPGAs let us quickly and easily develop different video signal bridging, aggregation and splitting applications for our industrial and automotive customers using just one device, saving us significant development time and resources.”
The CrossLink-NX family was designed using the new Lattice Nexus platform, which combines a 28 nm FD-SOI manufacturing process with a new, Lattice-designed, FPGA fabric architecture optimized for low power operation in a small form factor.
“Not only does CrossLink-NX lead in power consumption, form factor, reliability and performance in comparison to similar competing FPGAs, it is also supported by a robust library of design software, IP blocks and application reference designs,” said Gordon Hands, Director of Product Marketing, Lattice Semiconductor. “These make it quick and easy for developers to integrate CrossLink-NX FPGAs into new or existing Edge designs.”
Key features of the CrossLink-NX include:
- Low power – built on the Lattice Nexus FPGA platform, CrossLink-NX provides up to a 75 percent reduction in power consumption compared to competing FPGAs of a similar class.
- High reliability – CrossLink-NX has a Soft Error Rate (SER) up to 100 times lower than similar FPGAs in its class, making it a compelling solution for mission critical applications that must operate safely and reliably. The initial CrossLink-NX device is designed to support ruggedized environments found in outdoor, industrial, and automotive applications.
-
Performance – CrossLink-NX delivers enhanced performance enabled by three key elements:
- Fast I/O support – CrossLink-NX FPGAs are well-suited for embedded vision applications thanks to support for multiple fast I/Os, including MIPI, PCIe and DDR3 memory.
- Instant on performance – to better support applications where a long system boot time is unacceptable, such as industrial motor control, CrossLink-NX enables ultra-fast I/O configuration in 3 ms and total device configuration in less than 15 ms.
- High memory to logic ratio – to efficiently power AI inferencing in Edge devices, CrossLink-NX features 170 bits of memory for every logic cell, the highest memory to logic ratio in its class, providing 2x the performance compared to prior generations.
- Small form factor – to support customer system miniaturization, the first CrossLink-NX device is available in a 6 x 6 mm form factor which is up to ten times smaller than similar competing FPGAs in its class.
- Software tools and IP – in addition to its new Lattice Radiant 2.0 design software, Lattice offers a robust library of popular IP cores including interfaces like MIPI D-PHY, PCIe, SGMII and OpenLDI, and demos for common embedded vision applications such as 4:1 image sensor aggregation.
Originally scheduled for availability in 2020, Lattice is releasing CrossLink-NX ahead of schedule and is already sampling devices with select customers. For more information, please visit www.latticesemi.com/CrossLink-NX.
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo or Youku.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005349/en/
Contact information
MEDIA CONTACTS:
Bob Nelson
Lattice Semiconductor
408-826-6339
Bob.Nelson@latticesemi.com
INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
